Grant ID RP150245
Awarded On February 18, 2015
Title EGFR Arginine Methylations: Biomarkers for Cetuximab Resistance in colon cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Mien-Chie Hung
Cancer Sites Colorectal
Contracted Amount $900,000
Lay Summary

Epidermal growth factor receptor (EGFR) is a key enzyme that controls cell proliferation and growth, and is aberrantly activated in multiple human cancers. The EGFR inhibiting monoclonal antibody cetuximab (Erbitux) has been used to treat colorectal cancer (CRC) patients. Cetuximab alone or in combination with chemotherapy has shown efficacy in CRC treatment; however, significant numbers of patients exhibit resistance to cetuximab and the underlying mechanisms are not completely understood. Thus, it is extremely important to identify the subpopulation of EGFR-overexpressing CRC patients that will respond to treatment with cetuximab. In addition, understanding the mechanism of resistance for ...

Read More